Receiving Drugs Containing Selenium Does Not Reduce The Risk Of Lung Cancer

Receiving Drugs Containing Selenium Does Not Reduce The Risk Of Lung Cancer.
Taking the accepted mineral addendum selenium doesn't decrease the likelihood of lung cancer recurrence, a new study reveals. Lead author Dr Daniel D Karp, a professor in the area of thoracic head and neck medical oncology at the University of Texas MD Anderson Cancer Center, is scheduled to tip the finding Saturday at the American Society of Clinical Oncology annual meeting, in Chicago. "Several epidemiological and brute studies have long-suggested a connection between deficiency of selenium and cancer development," said Karp in a message release.

So "Interest and research escalated in the late 1990s after a skin cancer and selenium study, published in 1996, found no further against the skin cancer, but did suggest an approximate 30 percent reduction of prostate and lung cancers. Our lung cancer fact-finding and another major study for the prevention of prostate cancer evolved from that finding".

But the supplemental study found that among more than 1,500 stage 1 (early) non-small apartment lung cancer patients who had survived their initial bout with the disease, selenium offered no sponsorship against recurrence or the onset of a new cancer or second primary cancer. The patients were tracked from 2000 to 2009, after all had undergone surgery to slay their initial tumors and remained cancer-free for a nominal of six months post-treatment.

Half the patients were placed on a regimen of 200 micrograms of selenium, while the other half took a placebo. Those in the placebo gathering had better survival rates five years later than those taking the sequel - an observation that led the research team to halt the look earlier than planned.

While 78 percent taking the placebo stayed alive over that time frame, the classify was just 72 percent among the selenium group. And while 1,4 percent of the placebo bundle developed a second primary tumor within a year, that figure rose to 1,9 percent in the midst the selenium group, the researchers said neosize xl plus. Some benefit of selenium was observed in a small pile of patients who had never smoked, but the study authors said the group was too small to render the finding meaningful.